NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.

Istituto Nazionale di Ricovero e Cura per Anziani29 enrolled

Overview

Observational prospective study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the iniation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.

The purpose of the trixeo study is to conduct a prospective observational study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the initiation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

COPD

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * COPD; * Clinical indication for triple inhalation therapy with formoterol/glycopyrrolate/budesonide; Exclusion Criteria: * Life expectancy less than one year;

Locations (2)

INRCA Hospital

Ancona, Italy

RECRUITING

IRCCS INRCA Hospital

Osimo, Italy

RECRUITING

Outcomes

Primary Outcomes

Change in serum NT-pro-BNP levels

Before and 3 months after the introduction of bronchodilator therapy with formoterol/glycopyrrolate/budesonide, patients will be evaluated to assess serum NT-proBNP levels.

Time frame: Before and 3 months after the start of triple therapy with formoterol/glycopyrrolate/budesonide

Central Contacts

Anna Rita Bonfigli

CONTACT

0718003719 a.bonfigli@inrca.it

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.